We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement

Trovagene, BCBSIL Collaborate

Listen with
Speechify
0:00
Register for free to listen to this article
Thank you. Listen to this article using the player above.

Want to listen to this article for FREE?

Complete the form below to unlock access to ALL audio articles.

Read time: Less than a minute

Trovagene, Inc. has announced that it has signed an in-network provider agreement with the healthcare network Blue Cross Blue Shield of Illinois (BCBSIL) establishing health benefit access to the full line of Trovagene's tests and services.

"The agreement with BCBSIL takes us a step further in the execution of our access and reimbursement strategy that includes establishing relationships with leading national and regional payors," said Bill Welch, Chief Executive Officer of Trovagene.

"We are looking forward to offering oncologists and their patient's access to our Trovera™ urine and blood based liquid biopsy tests and enabling personalized cancer care." Trovagene now has contracts with payors covering approximately 168 million lives.

Increasing patient access by contracting with payors is one of the critical strategic components that support the adoption of Trovagene's clinical testing in late-stage solid tumor cancers.